| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6ed83b9d5c28c6c356d1d08d58501e7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-5161
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y40-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52 |
| filingDate |
2021-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bab9d5c244b569b09cdca07bf7cebec9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dc661e0aaeae9da2ca1c618e490dfa52 |
| publicationDate |
2022-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-113952465-A |
| titleOfInvention |
A kind of camptothecin prodrug and its preparation method and application |
| abstract |
The invention discloses a camptothecin prodrug and a preparation method and application thereof, belonging to the technical field of pharmaceutical preparations. The present invention utilizes the prodrug strategy to chemically bond the camptothecin to the low molecular weight heparin (low molecular weight heparin, LMWH) molecular chain to form the prodrug, and the synthetic compound is synthesized by the hydrophobicity of the camptothecin and the hydrophilicity of the low molecular weight heparin. LMWH‑CPT self-assembles to form nanoparticles. The camptothecin prodrug LMWH-CPT not only has the advantages of a polymer prodrug, but also the camptothecin molecule in the core of the nanoparticle relies on its own unique hydrophobic interaction to significantly increase the equilibrium constant pKa, ensuring its neutrality. It has a high closed-loop rate after storage in the environment and after injection. |
| priorityDate |
2021-10-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |